The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational...

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational...

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational...

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational...

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational...

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Optiscan Imaging and Monash University have agreed to work together on its its project to develop the next-gen gastrointestinal (GI) flexible...

By Zhou Chao Indian media has recently reported that the Indian Ministry of External Affairs stated that China and India have reached an agreement...

PyroGenesis (TSX:PYR), an ESG stock focused on industrial technology, signs a three-year, C$27 million contract with an existing U.S. client.